Pathstone Holdings
CYTK icon

Pathstone Holdings’s Cytokinetics CYTK Stock Holding History

Pathstone Holdings’s Portfolio CYTK Stock Details CYTK Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$4.06M Buy
47,633
+3,117
+7% +$224K 0.01% 741
2026
Q1 		$2.93M Sell
44,516
-883
-2% -$56.1K 0.01% 826
2025
Q4 		$2.88M Buy
45,399
+7,121
+19% +$443K 0.01% 839
2025
Q3 		$2.1M Buy
38,278
+13,600
+55% +$560K 0.01% 999
2025
Q2 		$815K Sell
24,678
-5,441
-18% -$189K ﹤0.01% 1491
2025
Q1 		$1.21M Buy
30,119
+3,825
+15% +$176K 0.01% 1279
2024
Q4 		$1.24M Sell
26,294
-8,266
-24% -$429K 0.01% 1249
2024
Q3 		$1.82M Buy
34,560
+5,027
+17% +$280K 0.01% 1029
2024
Q2 		$1.6M Buy
29,533
+10,615
+56% +$641K 0.01% 1035
2024
Q1 		$1.33M Buy
18,918
+7,943
+72% +$614K 0.01% 1113
2023
Q4 		$916K Buy
+10,975
New +$397K ﹤0.01% 1129

Other funds holding CYTK

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $153B AUM 38.14% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $11.1B AUM 207.82% 1-Year Est. Return
Bank of America
Bank of America Charlotte, North Carolina $1.55T AUM 33.47% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Pathstone Holdings's CYTK Position: Q2 2026 in Review

Pathstone Holdings increased its Cytokinetics (CYTK) stake by 7% in Q2 2026, buying an estimated $224K and bringing the position to 47,633 shares worth $4.06M. The position accounts for 0.01% of the portfolio, ranked #741.

Pathstone Holdings first reported a position in CYTK in Q4 2023 and has held it in 11 quarters since. 482 funds tracked by Wall St. Rank hold CYTK as of Q2 2026.

  • Pathstone Holdings held 47,633 shares of Cytokinetics worth $4.06M as of Q2 2026.
  • Pathstone Holdings bought 3,117 Cytokinetics shares in Q2 2026, an estimated $224K.
  • Cytokinetics made up 0.01% of Pathstone Holdings's portfolio in Q2 2026, its #741 holding.
  • Pathstone Holdings first reported a position in Cytokinetics in Q4 2023 and has held it in 11 quarters since.
  • 482 funds tracked by Wall St. Rank held Cytokinetics as of Q2 2026.

Based on Pathstone Holdings's 13F filing for Q2 2026, filed 13 Aug 2026.